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Prevention of HRSV infectionsncytial virus (HRSV) structural P protein, phosphorylated at serine (S) and
threonine (T) residues, is a co-factor of viral RNA polymerase. The phosphorylation of S54 is controlled by the
coordinated action of two cellular enzymes: a lithium-sensitive kinase, probably glycogen synthetase kinase
(GSK-3) β and protein phosphatase 2A (PP2A).
Inhibition of lithium-sensitive kinase, soon after infection, blocks the viral growth cycle by inhibiting
synthesis and/or accumulation of viral RNAs, proteins and extracellular particles. P protein phosphorylation
at S54 is required to liberate viral ribonucleoproteins (RNPs) from M protein, during the uncoating process.
Kinase inhibition, late in infection, produces a decrease in genomic RNA and infectious viral particles.
LiCl, intranasally applied to mice infected with HRSV A2 strain, reduces the number of mice with virus in
their lungs and the virus titre. Administration of LiCl to humans via aerosol should prevent HRSV infection,
without secondary effects.
© 2008 Elsevier Inc. All rights reserved.Introduction
Suitable tools to control HRSV infections are: vaccines (White-
head et al., 1999), antiviral compounds (Pastey et al., 2000;Bitko and
Barik, 2001), and neutralizing monoclonal antibodies (Zhao and
Sullender, 2005; Wu et al., 2008; Boivin et al., 2008). This diversity
responds to the different physiological characteristics of human
populations (babies and toddlers, elderly and immunocompromised
adults) mainly affected by lower tract respiratory infections, caused
by this pneumovirus of the Paramyxoviridae family (Hall, 2001).
To develop speciﬁc antiviral compounds is important to under-
stand how viral proteins work during the viral growth cycle,
particularly those involved in distinct processes of viral metabolism,
like viral RNA synthesis and extracellular particle formation. Those
viral proteins are ideal targets for antiviral compounds.
HRSV has a single strand RNA, of 15,222 nucleotides in length, as its
genome, that encodes 10 genes, in the following order 3′NS1-NS2-N-
P-M-SH-G-F-M2-L-5′. These genes express the corresponding viral
proteins, except for the M2 gene that expresses M2-1 and M2-2
proteins. The viral RNA is enwrapped by N protein in the helical
nucleocapsid (NC). To NC, L, P and M2-1 proteins are bound forming
the ribonucleoprotein complex (RNP). This complex is the inner part
of the virion, surrounded by the M protein, that connects it to thel rights reserved.membranous envelope inwhich the viral glycoproteins F, G and SH are
inserted (Collins and Crowe, 2007).
In the formation of the extracellular viral particles, M protein
plays a crucial role. It is included in membranous vesicles, when
expressed in the absence of the rest of the viral proteins (Asenjo
et al., 2005), in agreement with its role as the main determinant of
enveloped viral particle formation (Teng and Collins, 1998).
The structural P phosphoprotein is an essential co-factor of L
protein, the active viral RNA polymerase being the complex P–L. Its
role, during transcription and replication, is to locate L protein on
the NC template and to maintain N protein in a functional RNA
encapsidation state (N0) (Collins and Crowe, 2007). It is phosphory-
lated at several serine and threonine residues, by addition of
phosphate groups with different turnover. In Long strain P protein,
phosphate groups with low turnover, are added to S232 and
perhaps to S237 (Sanchez-Seco et al., 1995); with intermediate
turnover to S116, S117and /119 (Navarro et al., 1991); with high
turnover to S30, S39, S42, S45, S54 and perhaps to T46 (Asenjo et al.,
2005) and with very high turnover to T108. P protein phosphoryla-
tions with low and intermediate turnover are related to the
extracellular viral particle formation (Villanueva et al., 1991; Lu
et al., 2002; Asenjo et al., 2005; Villanueva et al., 2000).
Phosphorylation at T108 regulates the participation of M2-1 protein
in viral transcription (Asenjo et al., 2006).
An interaction between M and P proteins, inhibited by P
phosphorylation at S54, has been described (Asenjo et al., 2005).
The cellular phosphatase PP2A is involved in its control (Asenjo et al.,
Fig. 1. P protein is phosphorylated at S54 bya lithiumsensitive protein kinase. (A) P protein
was transiently co-expressedwith the small t SV40 antigen, labelledwith 35S-methione, in
the presence of 15mM LiCl or NaCl, and from the correspoding cellular extracts (Materials
andmethods) P proteinwas immunoprecipitated, using Pmonoclonal antibody RS1/P. The
immunoprecipitated proteins were fractionated by SDS-PAGE and visualised by auto-
radiography (Asenjo et al., 2006). (B) HRSV infected HEp-2 cells, between 24-30 h post-
infection were treated with 15mM LiCl or NaCl and labelled, between 27-30 h, with 35S-
methionine, in the presence (+) or in the absence (-) of OKA (Materials and methods). The
cellular extracts were obtained and processed as described in (A). The ratio P/HP was
determined by densitometry using the pCBAs program.
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cellular protein kinase GSK-3 (Moreno et al., 1996).
We resonated that if this cellular kinase is involved in P protein
phosphorylation at S54 and the detected P–M interaction (AsenjoFig. 2. Effect of lithium addition at different post-infection times, on viral protein
synthesis and/or accumulation. (A) Uninfected (lane M) or HRSV-infected (lanes I) HEp-
2 cells were untreated (lanes −) or treated with 15 mM LiCl, at the indicated times post-
infection (lower part of the panel). Forty eight hours post-infection, the corresponding
cellular extracts were obtained (Materials and methods). After quantitation, 20 μg of
total protein from the different cellular extracts were analysed by SDS-PAGE and
visualised by staining with Coomassie blue. (B) Different total protein amounts (lanes 1,
2 and 3 correspond to 12.5, 25 and 50 μg, respectively) from the different cellular
extracts were separated by SDS-PAGE and analysed by Western blot with an anti-HRSV
serum. In panels A and B, left part, the electrophoretical mobilities of MWmarkers (lane
MW) and those of proteins contained in puriﬁed extracellular viral particles (lane V) are
indicated. (C) The results shown in panel B, representative of those obtained in several
experiments, were quantiﬁed by densitometric analysis using the pCBas program. The
obtained values for the different viral proteins are expressed as percentages of the
values obtained in the absence of LiCl that were considered as 100%.et al., 2005) is related to RNP's inclusion intomature viral particles, the
inhibition of GSK-3 activity by LiCl salt, a practice widely used in the
treatment of bipolar human depression (Cade, 1949; Cade, 1999;
Tondo et al., 1997; Manji and Moore, 1999), could be used to limit
HRSV infections, by decreasing the RNA synthesis capacity of viral
RNPs, due to their premature interactionwith M protein. When GSK-3
is active, this interaction is delayed, due to P protein phosphorylation
at S54.
The obtained results testing this hypothesis, have indicated that
the inhibition of a lithium-sensitive kinase, probably the GSK-3 β
isoform, stops the viral growth cycle by blocking virus uncoating, the
reverse process of RNP's coating by M protein occurring during
extracellular viral particle formation (Lamb and Kolakfosky, 2005).
Later post-infection, the inhibition imbalances viral transcription-
replication, a phenotype displayed by a recombinant HRSV lacking
M2-2 protein (Bermingham and Collins, 1999).
The inhibitory effect of LiCl treatment on HRSV infection, was also
observed in animals, without secondary effects. Thus, this treatment
applied as an aerosol to the upper respiratory tract in humans, may
prevent HRSV infections.
Results
A cellular lithium-sensitive protein kinase is involved in P
protein phosphorylation at S54. Two phosphorylated serines in
HRSV P protein, those at positions 30 and 54, have the
recognition consensus sequence described for the kinase GSK-3
(Moreno et al., 1996) (SP or SXXXS⁎, being S⁎ in phosphorylated
form and S the target residue to be phosphorylated by GSK-3).Fig. 3. Effect of lithium addition, at different post-infection times, on viral RNAs
synthesis and/or accumulation. Panel A, half of the cultures analysed in Fig. 2 were
processed to obtain total RNA by Trizol method following the supplier's instructions.
Dilutions of these materials were used to quantify (indicated as log to base 10, in the
upper part), by semiquantitative RT-PCR, the amounts of cRNA plus mRNA and vRNA,
with oligonucleotides corresponding to genes P and M2, respectively. As an internal
control, β-actin mRNA was quantiﬁed. The ampliﬁed DNA fragments were analysed by
1% agarose gel electrophoresis in TBE buffer, visualised by staining with ethidium
bromide and quantiﬁed by the pCBAS program (see details in Materials and methods).
The average results of six experiments are shown in panel B, expressed as percentage of
values determined in the absence of LiCl. Value ranges are indicated.
Fig. 4. Effect of lithium addition, at different times post-infection, on the production of
extracellular viral particles. (A) Extracellular and infectious viral particles, produced by
the HRSV-infected cultures analysed in Figs. 2 and 3, were puriﬁed and titered,
respectively (see Materials and methods). Their protein composition, after SDS-PAGE
and staining with Coomassie blue and infectivities (upper part) are shown. The
experiment shown is a representative one of several carried out. V corresponds to
puriﬁed extracellular viral proteins. (B) Quantitation (by the pCBAS program) of physical
extracellular particles produced in three experiments similar to those analyzed in A. The
obtained values are expressed as percentages of that obtained for HRSV-infected HEp-2
cells, in the absence of LiCl. Value ranges are indicated.
Fig. 5. LiCl and SB 216763 treatments allow GSK-3 phosphorylation. 20 μg of total
protein from cellular extracts corresponding to mock (M) or HRSV-infected HEp-2 cells
(I) treated with 15 mM NaCl or LiCl or 10 μM SB 216763 from t0 to 48 h post-infection
were analysed by Western blot, ﬁrst with polyclonal antibodies from Cell signalling Cat
n° 9331 S that recognised phosphorylated GSK-3 α and β isoforms (A), then with
monoclonal antibody Biosource Cat n°44-610 that recognised nonphosphorylated α
and β isoforms (B) and then with anti-RS serum (C). V corresponds to puriﬁed
extracellular viral particles. The electrophoretical mobilities of viral proteins (left) and
those of GSK-3 α and β isoforms (right) are indicated.
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(Asenjo et al., 2005). It is only observed when PP2A is inhibited
and it produces a conformational change that decreases P protein
electrophoretic mobility, generating the P protein isoform HP
(Asenjo et al., 2005).
To determine if P proteinwas phosphorylated at S54 by the cellular
protein kinase GSK-3, P protein was expressed, after transfection or
HRSV infection of HEp-2 cells, in the presence of PP2A and GSK-3
inhibitors. SV40 small t antigen (Alberts et al., 1994) and okadaic acid
(Bialojan and Takai, 1988) were used to inhibit PP2A in transfected and
infected cells, respectively. As GSK-3 inhibitor, LiCl (Stambolic et al.,
1996) was used.
The synthetised proteins were labelled with 35S-methionine and
from the corresponding cell extracts, P protein was immunopreci-
pitated, fractionated by SDS-PAGE and visualised by autoradiogra-
phy. In Fig. 1, panel A, corresponding to transiently expressed P
protein in the presence of LiCl or NaCl, HP was only found in the
absence of LiCl treatment (NaCl, line), indicating that GSK-3 could be
the kinase involved in P protein phosphorylation at S54, when
expressed in the absence of the rest of the viral proteins. In Fig. 1,
panel B, it is shown that the synthesis and/or accumulation of HP
isoform, in HRSV-infected cells, was decreased (about 4 times) by
LiCl treatment. Thus, P protein phosphorylation at S54, in the
presence or in the absence of the rest of the viral proteins, iscontrolled by the coordinated action of a cellular lithium-sensitive
protein kinase, probably GSK-3 and phosphatase PP2A.
Effect of LiCl on HRSV infection
To determine how the lack of P protein phosphorylation at S54
affected the HRSV growth cycle, we analysed the effect of LiCl on
HRSV-infected HEp-2 synthesis and/or accumulation of the following
viral products:
Intracellular viral proteins
HEp-2 cells were treated for 48 h with 5, 10, 15, 20 and 50 mM LiCl
and the effects of the treatments on cell morphology (observed by
phase-contrast microscope), cell viability (determined by permeabil-
ity to trypan blue) or synthesis/and accumulation of proteins
(analysed by SDS-PAGE) were determined (data not shown). Only
50 mM LiCl treatment produced swelling and detachment of HEp-2
cells from the tissue culture plate. At the other lithium concentrations
no effects were observed.
The treatment effects of 15 mM LiCl on HRSV-infected HEp-2 cells
were determined at 2, 10, 24 and 30 h post-infection. Mock or
infected untreated cells (−), were included as controls. Forty eight
hours post-infection, the cultures were divided in two parts. From
one part, the cells and media were separated and soluble proteins
and extracellular viral particles, respectively, were obtained. In Fig. 2,
panel A, the protein composition of soluble protein fractions, after
SDS-PAGE separation and staining with Coomassie blue is shown. It
can be observed that, at early times post-infection, lithium treatment
drastically inhibited the synthesis and/or accumulation of viral
proteins. Later on only a slight decrease in synthesis and/or
accumulation of viral proteins was observed.
In order to quantify the decrease in synthesis and/or accumulation
of different viral proteins after 15 mM LiCl treatments, two different
amounts of total protein from infected cells were analysed byWestern
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these data (Fig. 2, panel C), has indicated that the amount of the
different viral proteins, was reduced between 97–50% when the
lithium-sensitive protein kinase was inhibited early post-infection. At
later post-infection times, kinase inhibition resulted in a decrease by
70–30% of different viral proteins, except for N and P proteins whose
decrease was only 10%. In both situations, the viral proteins most
affected were, in this order: F, M2-1, G and M, while N and P proteins
were less affected.
Viral RNAs
Total RNA was obtained from the other half of cultures before
analysed. The relative amounts of vRNA (genomic) and cRNA
(antigenomic) plus mRNA, were quantiﬁed by using speciﬁc oligonu-
cleotides of P and M2 genes, ﬁrst by RT (reverse transcription) and
then PCR (polymerase chain reaction), using different amounts of total
RNA. The amount of β-actin mRNAwas also quantiﬁed, in all cases, as
an internal control. The results obtained and their quantiﬁcation are
shown in Fig. 3. LiCl treatment of HRSV-infected HEp-2 cells, at early
and late post-infection times, inhibited intracellular vRNA by about 90
and 75%, respectively. In contrast, the production of c and mRNA was
inhibited by 90%, when the LiCl was added at early post-infection
times but not later. Here, the increase was 50%.
Production of infectious and extracellular viral particles
The amount of physical and infectious extracellular viral particles,
present in the culture media, were determined after partial puriﬁca-Fig. 6. LiCl treatment of HRSV-infected HEp-2 cells inhibits viral uncoating. Immunoﬂuoresc
moi 1. Adsorption, at 4 °C t for 2 h and then infection at 37 °C, were carried out in the presenc
cover slips were processed as indicated in Materials and methods. The immunoﬂuorescence
against M and P protein, respectively, as primary antibodies. As secondary antibodies anti-mo
were used. The analyses were done using a Radiance 2100 confocal laser scanning system (Btion (Villanueva et al., 1991) and plaque assay, respectively. The results
shown in Fig. 4 have indicated that physical and infectious
extracellular viral particles were decreased by 85% and 16 fold,
respectively, when infected cells were treated with LiCl at early times
post-infection. When the treatment was done late post-infection, only
30% and 2 fold reductions respectively, were detected. The difference
in decrease of genomic RNA (75%) and that of physical extracellular
viral particles (30%) suggests that the morphogenetic process,
required to transform RNPs into extracellular viral particles, could
be more efﬁcient in the absence of P protein phosphorylation at S54,
as anticipated.
The LiCl effect correlates with a decrease in GSK-3 activity
To rule out any effect of LiCl different than that of GSK-3
inhibition, like inhibition of inositol monophosphatase (IMP)
(Quiroz et al., 2004) or other protein kinases, HRSV-infected cells
were treated, at early times post-infection, with LiCl and 1 mM
inositol to revert the inhibitory effect of LiCl on IMP or with SB
216763, another speciﬁc inhibitor of GSK-3 (Bain et al., 2007). The
results obtained with LiCl and 1 mM inositol were identical to
those shown in Figs. 2 and 3 (not shown). With SB 216763, at
concentrations between 2 and 60 μM, no inhibition of viral proteins
and extracellular particle production was observed (data not
shown). It has been indicated that lithium treatment inactivates
GSK-3 α and β isoforms, through its phosphorylation at S21 and S9,
respectively (Li et al., 2007). However, it is not known if theence assays. HEp-2 cells, growing in cover slips, were infected with HRSV Long strain at
e of 15 mMNaCl or LiCl. At 0, 3 and 8 h post-adsorption, the media was removed and the
assays were developed with a monoclonal antibody and a monospeciﬁc rabbit serum
use and anti-rabbit IgG, conjugated with Alexa-488 (green) and Cy-5 (red), respectively,
io Rad Laboratories). Samples corresponding to 0 and 8 h post-adsorption, are shown.
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corresponding to HRSV-infected HEp-2 cells treated with NaCl, LiCl
or with SB 216763, were analysed by Western blot (Fig. 5) with
polyclonal antibodies that recognised GSK-3 α and β isoforms
phosphorylated at S21 and S9, respectively (panel A), with a
monoclonal antibody that recognises both GSK-3 isoforms (panel B)
and with anti-RS serum (panel C). The results have indicated that
LiCl addition to HEp-2 cells, allowed a higher phosphorylation on
the GSK-3 β isoform than that occurring in the presence of SB
21673 (panel A). Also, it is shown that SB 21675 addition resulted in
a signiﬁcant increase in S21 phosphorylation of GSK-3 α, suggesting
a different effect of lithium and SB 21675 on each GSK-3 isoform.
The results could indicate that GSK-3 β-isoform is the cellular
protein kinase activity involved in P protein phosphorylation at S54,
early post-infection. It is noteworthy that GSK-3 β is associated
with extracellular viral particles (lane V).
The treatment of HRSV-infected HEp-2 cells with LiCl inhibits viral
uncoating
The inhibition of P protein phosphorylation at S54, during HRSV
infection, has two main effects. At early times (between 2 and 10 hFig. 7. LiCl treatment of HRSV-infected HEp-2 cells inhibits viral uncoating. Quantitation
corresponds to an immunoﬂuorescence assay similar to that shown in Fig. 6 for individual M
them, ﬁrst a co-location mask and then a counting mask were obtained (right part of the ﬁgu
corresponding to the results obtained in three different experiments. The values were obtain
each experimental condition. Value ranges are indicated by bars. Values are expressed as ppost-infection), the inhibition of P protein phosphorylation, at this
residue, impaired the viral growth cycle, suggesting that early steps of
the viral growth cycle are being avoided. By contrast, this P protein
phosphorylation inhibition, at later times (between 10 and 30 h post-
infection), produced an increase in the amount of viral mRNAs and
decrease in that of vRNA. This imbalance has been related to the
absence of M2-2 protein activity (Bermingham and Collins, 1999).
Since at the beginning of the infection, intracellular viral antigens
were poorly detected in the infected cultures treated with LiCl, we
reasoned that the early viral growth cycle step, abolished in the
absence of P protein phosphorylation at serine residue 54, must occur
after adsorption and fusion processes. Thus, that step could be viral
uncoating.
Synchronised HRSV-infected HEp-2 cells were treated with
15 mM LiCl or NaCl. At different post-adsorption times, immuno-
ﬂuorescence assays were carried out using a monoclonal mouse
speciﬁc M protein antibody and a monospeciﬁc anti-P rabbit
serum. The samples were analysed by confocal immunoﬂuores-
cence microscopy.
The results in Fig. 6, have shown that bothviral antigenswere located
inpunctuated structures (panelsMand P). These structureswere similar
to the intracellular inclusions previously described (Garcia et al., 1993)of M and P proteins co-localised in punctuated structures. Panel A, the ﬁrst column
and P antigens. Column 2 corresponds to individual image masks for each antigen. From
re), by applying the programs indicated in Materials and methods. Panel B, quantitation
ed by applying the analyses shown in panel A to eight different images, corresponding to
ercentages of those obtained at t0 post-adsorption that was considered as 100%.
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both viral antigens co-localised (merge panels), indicating that RNPs
were surrounded by M protein. The punctuated structures in which M
and P proteins co-localised were counted. An example of that counting,
following the procedures indicated in Materials and methods, is shown
in Fig. 7A. From immunoﬂuorescence images for M and P proteins, two
imagemaskswere obtained, from them a co-localisationmask and from
it a counting mask, after elimination of nonco-localised signals. The
quantiﬁcationof thedata is indicated in Fig. 7B. Following the adsorption
period (t0), the number of punctuated structures in which M and P
proteins co-locate was similar in both HRSV-infected HEp-2 cells,
treatedwith NaCl or LiCl. After 3 and 8 h, the number of these structures
increased twofold in infected cells treated with LiCl but decreased by
half in those treated with NaCl. In these cultures, 24 h post-infection, P
protein but not M protein remained in the cytoplasmic inclusions (data
not shown), suggesting that P proteinphosphorylation at S54 is required
for M protein liberation from RNPs of infecting virus.
Effect of 15 mM LiCl treatment in mice intranasally infected with HRSV
A2 strain
Three groups of 10 female mice Balb/c were intranasally infected
with HRSV A2 strain. At different times post-infection, each group was
treated with 15 mM NaCl, 15 mM LiCl or H2O. Ninety six hours post-
infection, the mice were killed and the titres of HRSV in lungs were
determined by limiting dilution. The results are shown in Table 1.
Among the mice treated with LiCl, 62% of them had no HRSV in their
lungs, whereas all those treated with NaCl or H2O had it. In addition,
the lung virus titre of infected mice treated with LiCl, was, at least, 2
log units lower than that found in 37.5% of untreated infected animals.
No differences in body weight or fur appearance were observed
among the different mouse groups, except for a reduced morbidity in
LiCl treated animals. Thus, nasal application of LiCl, after HRSV
infection, decreased the amount of infected mice and the amount of
infectious virus in their lungs.
Discussion
To develop speciﬁc antiviral compounds is important to delimitate
genuine viral processes, like RNA synthesis and morphogenesis in
Paramyxoviruses. Viral RNPs participate as essential partners in both,
without counterparts in humans. Thus, RNP proteins are ideal targets
for such compounds without side effects on host cells. To design them,
it is important to know how RNP proteins work.
Phosphoprotein P, an RNP component, that forms with L protein
the viral RNA polymerase, can make interactions with itself, NC, N0,
M2-1 and M proteins, that are essential for viral growth (KhattarTable 1
Effect of LiCl treatment on HRSV-infected mice. Three groups of 10 female 9 weeks old
Balb/c mice were intranasally infected with 50 μl, via their nostrils, of HRSV A2 strain
(1×108 pfu/ml)
Group Treatment Infected mice % Titre/lung
(total pfu)
% of infected mice
with each titre
A LiCl (15 mM) 38 2×101–2×102 60
2×102–2×103 40
B NaCl (15 mM) 100 2×101–2×102 62.5
2×102–2×103 12.5
2×103–2×104 25
C H20 100 2×102–2×103 100
At 4, 10, 24, 32, 48, 52, 72 and 82 h post-infection, each group was treated with 50 μl by
nostril of 15 mM LiCl (group A), 15 mM NaCl (group B) or H2O (group C) and 96 h post-
infection the mice were killed. The infectious virus titre in the lungs was determined by
limiting dilution. A range of virus titre was deduced (see Materials and methods). The
percentage of infected animals in each group (those with detectable virus in their
lungs), the titre detected and percentage of infected animals showing different titres,
are indicated.et al., 2001; Mallipeddi et al., 1996; Mason et al., 2003; Asenjo et al.,
2006). P protein phosphorylations at T108, S116 and T210 are
required for viral RNA synthesis, where it acts as a tetramer (Asenjo
et al., 2008) whereas modiﬁcation of P protein at S116, S117, S119
and S232 could have a role in viral morphogenesis (Villanueva et al.,
1991; Lu et al., 2002). High turnover phosphorylation at S54,
removed by PP2A, inhibits P protein incorporation into M-induced
extracellular membranous vesicles (Asenjo et al., 2005).
This paper shows that P protein phosphorylation at S54 was done
by a lithium-sensitive kinase, that could be the GSK-3 β isoform. This
phosphorylation is required for viral uncoating, the process that
liberates infecting viral particle RNPs from M protein, making them
active for primary transcription (Lamb and Kolakofsky, 2005). Late
post-infection, the lithium-sensitive kinase activity seems to be
required for M2-2 protein function.
The GSK-3 action on P protein modiﬁcation at S54, is supported by
the diminished production, in transfected or HRSV-infected HEp-2
cells, of HP isoform (generated by P protein phosphorylation at S54), in
the presence of GSK-3 and PP2A inhibitors.
Inhibition of S54 P protein phosphorylation, early after infection,
results in a residual viral product production. This suggests a viral
infection arrest after the adsorption and fusion processes. In the
absence of LiCl sensitive protein kinase activity, viral particles
internalise without M protein liberation, suggesting that the early
step in the HRSV growth cycle that requires P protein phosphorylation
at S54 is that of viral uncoating. In agreement with this, P protein
phosphorylation at S54 is never found in extracellular viral particles
(Asenjo et al., 2005). The effects on HRSV infection due to GSK-3
activity inhibition, seem to be M protein mediated since no defects on
viral RNA synthesis, in a HRSV based minireplicon system, have been
detected for P protein variants with substitutions S54D or S54A
(Asenjo et al., 2005). These variants simulate full activity or absence of
lithium-sensitive kinase, on P protein.
To conﬁrm that GSK-3 inhibition produces the described effects,
LiCl action exerted on IMP (Quiroz et al., 2004) was ruled out (by
adding LiCl and 1 mM inositol) and SB 216763, another speciﬁc GSK-3
inhibitor was tested. No effect was produced by treatment of HRSV-
infected cells with different SB 216763 concentrations. In most cells,
including HEp-2, there are two GSK-3 isoforms, α and β (Bhat and
Budd Haeberlin, 2004). Although both GSK-3 inhibitors used may
allow GSK-3 α and ß-isoform inactivation by phosphorylation at S21
and S9, respectively (Li et al., 2007) (Fig. 5), LiCl inactivates the βmore
than the α isoform, whereas SB 216763 does the opposite (Fig. 5).
Therefore, the lithium-sensitive protein kinase, involved in P protein
phosphorylation at S54, could be the GSK-3 β isoform. This isoform is
present in extracellular viral particles (Fig. 5). This presence could
overcome the Akt inhibitory effect on the GSK-3 β isoform (Sun et al.,
2008) early post-infection, to avoid cell apoptosis (Peters et al., 2008).
However, other kinases, inhibited by LiCl in vitro, could be involved
on S54 P protein phosphorylation, includingMPAK-integrating protein
kinases (MNK1,MNK2), smooth-muscle myosin light-chain kinase
(smMLCK), phosphorylase kinase (PHK), checkpoint kinase (CHK),
homeodomain-interacting protein kinase 3 (HIPK3) inhibitory κß
kinase and TANk-binding kinase (Bain et al., 2007). However, the
presence of all these kinases in HEp-2 cells is uncertain.
HIPK3 is a Fas/FADD-interacting serine/threonine kinase that
induces Fas-associated death domain (FADD) phosphorylation, prob-
ably at S196 (Rochat-Steiner et al., 2000) and inhibits Fas-mediated
Jun-NH2-terminal kinase activation. FADD primary sequence around
this residue is SPMSW, similar to that of P protein S54 (SPITS). Thus,
HIPK3 could be also involved in P protein phosphorylation at S54.
LiCl also has an inhibitory effect on mice intranasal infected with
HRSV. Intranasal administered, LiCl reduces the number of infected
animals, virus titres (Table 1) and morbidity.
Lithium salts have been widely used by ingestion for more than
50 years, for the clinical treatment of human psychiatric disorders
32 A. Asenjo et al. / Virology 380 (2008) 26–33(Cade, 1949; Tondo et al., 1997; Manji and Moore, 1999; Cade, 1999).
Therefore, besides its modest reduction in HRSV infections in
animals, they could be a safe preventive treatment for acute HRSV
infections, especially in patients for whom these infections repre-
sent a dangerous risk. It could also be useful to reduce HRSV
infections spreading in hospitals, intensive care units and day care
centres occupied by babies, toddlers, the immunocompromised and
elderly adults.
Materials and methods
Cells and viruses
HEp-2 cells were obtained from the American tissue culture
collection. The HRSV Long and A2 strains and the vaccinia recombi-
nant virus vTF-3 were used through this study. The conditions for
growing, handling and viral titre determinations were previously
described (Asenjo et al., 2006; Villanueva et al., 1991).
Transfection and HRSV infection in HEp-2 cells. Treatments with LiCl and
GSK-3 inhibitors. Isotopic radioactive labelling and analysis of synthetised
viral proteins. Immunoprecipitation of P protein. Western blot
HEp-2 cells (growing in 8 cm2 diameter tissue culture plates)
were infected vTF-3 at moi 5 and then cotransfected with 2.5 μg of
total DNA from pGEM3 recombinant plasmids containing HRSV P
gene cDNA and SV40 small t antigen DNA (Asenjo et al., 2005). Ten
hours posttransfection the cells were labelled with 35S-methionine
30 μCi/ml; 1000 Ci/mM, for 3 h, in DMEM medium without
methionine, containing 15 mM NaCl or LiCl and the corresponding
soluble protein fractions were obtained as followed . The cells were
scraped separated from media, washed twice with PBS and
resuspended in 10 mM Tris–HCl pH 7.5, 140 mM NaCl, EDTA
5 mM, TX-100 1%, DOC 1%. After centrifugation at 12,000 g for
15 min at 4 °C, the supernatant was separated and it was considered
as the soluble protein fraction (Asenjo et al., 2005).
HEp-2 cells were mock or HRSV Long strain infected at moi 1. After
2 h of adsorption the virus was removed and DMEM medium
supplemented with 2.5% inactivated new born calf serum, 2%
glutamine and 1% antibiotics. 15 mM LiCl or NaCl or 10–60 μM SB
216763, were added at the indicated post-infection times. Metabolic
labelling with 35S-methionine 24 h post-infection, for 3 h, in DMEM
without methionine, in the presence of 100 nM okadaic acid (OKA)
and preparation of the corresponding soluble protein fractions (48 h
post-infection) was as described previously (Asenjo et al., 2005). From
the media the extracellular viral particles were partially puriﬁed by
precipitation twice with 6% polyethylene glycol (PEG) 6000 (Villa-
nueva et al., 1991).
The proteins from the corresponding soluble fractions, were
immunoprecipitated with speciﬁc P protein monoclonal antibody
RS1/P, in the cellular extract buffer containing 0.1% DOC, 0.1% SDS and
BSA 0.1 mg/ml. After adding rabbit anti-mouse IgG and Staphilococcus
aureus Cowan I strain, the immune complexes were recovered under
the previously described conditions (Asenjo et al., 2006). They were
separated by SDS-PAGE (12% acrylamide) and visualised by Coomassie
blue staining or by autoradiography.
To quantify the amount of the different viral proteins synthesised
and/or accumulated after treatment with LiCl at different times post-
infection,Western blot was developed. Twelve point ﬁve, 25 and 50 μg
of total protein were separated, transferred to Inmobilon membrane
(Villanueva et al., 1991) and incubated with a rabbit serum against
HRSV puriﬁed extracellular viral particles, as previously described
(Rodriguez et al., 2004).
To detect phosphorylated or nonphosphorylated GSK-3 isoforms,
polyclonal antibody Cell Signalling Cat n° 9331S and monoclonal
Biosource Cat n° 44-610, diluted 1:1000, respectively, were used.Quantitation of the different viral RNAs synthetised
Total RNA was obtained by Trizol method, 48 post-infection from
mock or HRSV-infected HEp-2 cells, untreated or treated with 15 mM
LiCl, at the indicated times post-infection, following the suppliers'
indications. The different viral RNAs (vRNA, cRNA and mRNAs) were
quantiﬁed by RT-PCR. Different amounts of total RNA from the
different HRSV-infected HEp-2 treated cultures were used for RT-PCR,
using the oligonucleotides PmRNA (1–20), PvRNA (622–641),
M2mRNA (1–26) and M2vRNA (691–714). The numbers indicate the
position of oligonucleotide sequences on the cDNA corresponding to
mRNAs of the chosen genes. m and v mind plus and minus polarities,
respectively. The RT reaction was carried out using AMVTf and the
appropriated oligonucleotide (plus sense to amplify vRNA or minus
sense to amplify c and mRNA) following the suppliers' indications, at
42 °C for 45 min, 94 °C for 2 min and 4 °C. Then, the contrary sense
oligonucleotide was added together with TfI DNA polymerase. The
PCR reaction was 40 cycles at 94 °C for 30 s, 55 °C for 1 min and 68 °C
for 2 min. Then, the samples were incubated at 68 °C for 7 min and
cooled to 4 °C.
The ampliﬁed DNA fragments were analysed by 1% agarose gel
electrophoresis in TBE buffer, visualised by staining with ethidium
bromide and quantiﬁed by a pCBAS program. As an internal control,
β-actin mRNA was quantiﬁed in a parallel experiment using the
speciﬁc oligonucleotides and conditions that have been previously
described (Martinez et al., 2001). The obtained arbitrary values of
ampliﬁed DNAs were represented against dilutions of total RNA. The
dilutions producing the same amount of ampliﬁed DNA were used
for the relative determinations of different viral RNA amounts
present in each sample.
Immunoﬂuorescence assays
HEp-2 cells growing in cover slips and HRSV Long strainwere used
for infections. First, adsorption at 4 °C for 2 h, then infection at 37 °C
were carried out in the presence of the corresponding salt. At the
indicated post-adsorption times the media was removed, the cover
slips were washed twice with PBS, and the cells were ﬁxed by
treatment with PBS containing 4% formaldehyde, for 10 min at 4 °C.
The ﬁxation solution was removed and the cover slips were
maintained in PBS containing 2% sodium azide at 4 °C.
The immunoﬂuorescence assays were developed by following
previously described conditions (Sullivan et al., 1994). A monoclonal
antibody and a monospeciﬁc rabbit serum against M and P proteins, at
dilutions 1:400 and 1:200, respectively, were used as primary
antibodies. The monoclonal antibody anti-M was a generous gift of
Dr. Ghildyal. As secondary antibodies anti-mouse and anti-rabbit IgG,
conjugated with Alexa-488 (molecular Probes, Eugene, CA) and Cy-5
(Biological Detection systems, Inc., Pittsburgh, P.A), at 1:100 and 1:500
dilutions, respectively, were used. Microscopy was performed using a
Radiance 2100 confocal laser scanning system (Bio Rad Laboratories)
built on a Nikon Eclipse TE 300 epiﬂuorescence microscope using the
40× oil-immersion planapo objective NA=1.3 and a 1.8× digital zoom.
Images were collected at 512×512 pixel (1 pixel=0.33 μm) from a
single focal plane (ca.0.64 μm) using a Kalman ﬁlter to average three
scans at 50 lines per second.
To quantify punctuated structures we used the public domain
software imageJv.1.32j (Wayne Rasband, National Institute of Health
http://rsb.info.nih.gov/ij/Java1.3.1_03). To each image was applied
the Find edges, Threshold (128–255) and Analyze Particles (20 to
200 pixel in size) actions to obtain an image mask. Image masks
corresponding to P and M proteins, from the same optical ﬁeld, were
used to obtain a new co-localisation mask using Co-localisation
plugin. Co-localisation values were obtained applying the Analyze
Particles action to the co-localisation mask, to render the counting
mask.
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Three groups of 10 female mice Balb/c, 9 weeks old, were infected
with 50 μl, via the nostrils, of HRSVA2 strain, containing 1×108 pfu/ml.
At 4, 10, 24, 32, 48, 72 and 86 h post-infection, each group was treated
with 50 μl by the nostrils of 15 mMNaCl, 15 mM LiCl or H2O. Ninety six
hours post-infection, themice were killed and the HRSV titres in lungs
determined by limiting dilution assay. A range of virus titres,
expressed as pfu per mouse lung, was obtained by considering the
two consecutive dilutions in each case that produced HEp-2 total and
partial lysis and the inoculation volume used.Acknowledgments
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